Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists

被引:21
作者
Didiuk, Mary T. [1 ]
Griffith, David A. [1 ]
Benbow, John W. [1 ]
Liu, Kevin K. C. [1 ]
Walker, Daniel P. [1 ]
Bi, F. Christopher [1 ]
Morris, Joel [1 ]
Guzman-Perez, Angel [1 ]
Gao, Hua [1 ]
Bechle, Bruce M. [1 ]
Kelley, Ryan M. [1 ]
Yang, Xiaojing [1 ]
Dirico, Kenneth [1 ]
Ahmed, Syed [1 ]
Hungerford, William [1 ]
DiBrinno, Joseph [1 ]
Zawistoski, Michael P. [1 ]
Bagley, Scott W. [1 ]
Li, Jianke [1 ]
Zeng, Yuan [1 ]
Santucci, Stephanie [1 ]
Oliver, Robert [1 ]
Corbett, Matthew [1 ]
Olson, Thanh [1 ]
Chen, Chiliu [1 ]
Li, Mei [1 ]
Paralkar, Vishwas M. [1 ]
Riccardi, Keith A. [1 ]
Healy, David R. [1 ]
Kalgutkar, Amit S. [1 ]
Maurer, Tristan S. [1 ]
Nguyen, Hang T. [1 ]
Frederick, Kosea S. [1 ]
机构
[1] Pfizer Inc, Res & Dev, Groton, CT 06340 USA
关键词
Osteoporosis; Human parathyroid hormone; Calcium receptor antagonists; Pharmacokinetics; SAR exploration; PARATHYROID-HORMONE SECRETION; NONSPECIFIC-BINDING; OSTEOPOROSIS; BONE; RATS; MICROSOMES; DISCOVERY;
D O I
10.1016/j.bmcl.2009.07.004
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Synthesis and structure-activity relationship (SAR) studies on 5-trifluoromethylpyrido[4,3-d] pyrimidin-4(3H)-ones, a novel class of calcium receptor antagonists is described with particular emphasis on optimization of the pharmacokinetic/pharmacodynamic parameters required for a short duration of action compound. Orally-active compounds were identified which displayed the desired animal pharmacology (rapid and transient stimulation of parathyroid hormone) essential for bone anabolic effects. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4555 / 4559
页数:5
相关论文
共 21 条
[1]   Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Parathyroid Hormone-Calcium Homeostasis in Rats and Humans [J].
Abraham, Anson K. ;
Mager, Donald E. ;
Gao, Xiang ;
Li, Mei ;
Healy, David R. ;
Maurer, Tristan S. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 330 (01) :169-178
[2]   A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo [J].
Arey, BJ ;
Seethala, R ;
Ma, ZP ;
Fura, A ;
Morin, J ;
Swartz, J ;
Vyas, V ;
Yang, W ;
Dickson, JK ;
Feyen, JHM .
ENDOCRINOLOGY, 2005, 146 (04) :2015-2022
[3]   Teriparatide A Review of its Use in Osteoporosis [J].
Blick, Stephanie K. A. ;
Dhillon, Sohita ;
Keam, Susan J. .
DRUGS, 2008, 68 (18) :2709-2737
[4]   Potential new drug targets for osteoporosis [J].
Deal, Chad .
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2009, 5 (01) :20-27
[5]   In silico modeling of nonspecific binding to human liver microsomes [J].
Gao, Hua ;
Yao, Lili ;
Mathieu, Heather W. ;
Zhang, Ying ;
Maurer, Tristan S. ;
Troutman, Matthew D. ;
Scott, Dennis O. ;
Ruggeri, Roger B. ;
Lin, Jing .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (10) :2130-2135
[6]   MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF HUMAN PARATHYROID CALCIUM RECEPTOR CDNAS [J].
GARRETT, JE ;
CAPUANO, IV ;
HAMMERLAND, LG ;
HUNG, BCP ;
BROWN, EM ;
HEBERT, SC ;
NEMETH, EF ;
FULLER, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (21) :12919-12925
[7]   Discovery of novel 1-arylmethyl pyrrolidin-2-yl ethanol amines as calcium-sensing receptor antagonists [J].
Gavai, AV ;
Vaz, RJ ;
Mikkilineni, AB ;
Roberge, JY ;
Liu, YL ;
Lawrence, RM ;
Corte, JR ;
Yang, W ;
Bednarz, M ;
Dickson, JK ;
Ma, ZP ;
Seethala, R ;
Feyen, JHM .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (24) :5478-5482
[8]   Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats [J].
Gowen, M ;
Stroup, GB ;
Dodds, RA ;
James, IE ;
Votta, BJ ;
Smith, BR ;
Bhatnagar, PK ;
Lago, AM ;
Callahan, JF ;
DelMar, EG ;
Miller, MA ;
Nemeth, EF ;
Fox, J .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (11) :1595-1604
[9]   Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis [J].
Hodsman, AB ;
Hanley, DA ;
Ettinger, MP ;
Bolognese, MA ;
Fox, J ;
Metcalfe, AJ ;
Lindsay, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11) :5212-5220
[10]   Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency [J].
Miller, MA ;
Chin, J ;
Miller, SC ;
Fox, J .
BONE, 1998, 23 (03) :257-266